Rociletinib

Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.[1] It was being developed by Clovis Oncology as a potential treatment for non-small-cell lung cancer.[1] In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew its marketing authorisation application from the European Medicines Agency.[1]

Rociletinib
Clinical data
Trade namesXegafri
Other namesCO-1686, AVL-301
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC27H28F3N7O3
Molar mass555.562 g·mol−1
3D model (JSmol)

References

  1. Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E (2016). "New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?". OncoTargets and Therapy. 9: 6065–6074. doi:10.2147/OTT.S97644. PMC 5063481. PMID 27785053.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.